Crestor
-
Cholesterol Drug Cuts Heart Risk
Data from a study presented at the American Heart Association Scientific Sessions demonstrated that Crestor (rosuvastatin calcium) reduced major cardiovascular (CV) events by 44% compared to placebo. It also reduced the combined risk of cardiovascula…
Crestor | 30 December 2008
-
Crestor breakthroughs in major clinical study
AstraZeneca has announced the first statin monotherapy to achieve regression of coronary atherosclerosis by angiography in a major clinical study. The company says Crestor (rosuvastatin) is the only statin to show regression of coronary atheroscle…
Crestor | 28 April 2008
